Table 5.
STL and mSTL outcomes for survival and development of varices and ascites in the validation cohorta
| Validation | |||||
|---|---|---|---|---|---|
| STL | Green | Amber | Red | Total | |
| Survival | Alive | 202 | 258 | 148 | 608 |
| Dead | 0 | 9 | 24 | 33 | |
| Varices | No | 202 | 267 | 148 | 617 |
| Yes | 0 | 0 | 24 | 24 | |
| Ascites | No | 202 | 265 | 152 | 619 |
| Yes | 0 | 2 | 20 | 22 | |
| Total | 202 | 267 | 172 | 641 | |
| mSTL | |||||
| Dead = 1 | Alive | 231 | 235 | 92 | 558 |
| Dead | 1 | 5 | 24 | 30 | |
| Varices | No | 232 | 237 | 98 | 567 |
| Yes | 0 | 3 | 18 | 21 | |
| Ascites | No | 231 | 238 | 99 | 568 |
| Yes | 1 | 2 | 17 | 20 | |
| Total | 232 | 240 | 116 | 588 | |
a
The numbers in the STL cohort are higher because it is still possible to use the simple algorithm to calculate the STL grade with a missing blood result.